Morse Michael A, Hall Joseph Robert, Plate Janet M D
Duke University Medical Center, Durham, NC, USA.
Expert Opin Biol Ther. 2009 Mar;9(3):331-9. doi: 10.1517/14712590802715756.
Vaccines for pancreatic cancer have been challenged by a number of factors, especially the immunosuppressive microenvironment within the tumor that allows for escape from immune surveillance.
OBJECTIVE/METHODS: We sought to identify results that define mechanisms of pancreatic-cancer-associated immunosuppression and strategies that might be useful to overcome them thereby resulting in effective immune responses to cancer vaccines capable of deleting pancreatic cancer cells.
RESULTS/CONCLUSION: Immunosuppressive tumor-associated macrophages (TAMs), myeloid-derived suppressor cells (MDSC), and regulatory T cells (Treg) reside in tumors, and their products along with tumor derived products (such as VEGF, TGFbeta and IL-10), create a microenvironment that counters immune activation and attack. Immunotherapy with cancer vaccines must include strategies to modulate these immunosuppressive cell types and tumor byproducts. Clinical trials are beginning to test these strategies.
胰腺癌疫苗面临诸多因素的挑战，尤其是肿瘤内的免疫抑制微环境，使得肿瘤细胞能够逃避免疫监视。
目的/方法：我们试图确定能够定义胰腺癌相关免疫抑制机制的结果，以及可能有助于克服这些机制从而对能够清除胰腺癌细胞的癌症疫苗产生有效免疫反应的策略。
结果/结论：免疫抑制性肿瘤相关巨噬细胞（TAM）、髓源性抑制细胞（MDSC）和调节性T细胞（Treg）存在于肿瘤中，它们的产物以及肿瘤衍生产物（如血管内皮生长因子、转化生长因子β和白细胞介素-10）营造了一个对抗免疫激活和攻击的微环境。癌症疫苗免疫疗法必须包括调节这些免疫抑制细胞类型和肿瘤副产物的策略。临床试验已开始对这些策略进行测试。
